What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Immune system
Michael Kirschfink focuses on Complement system, Immunology, Factor H, CD46 and Alternative complement pathway.
His work in Complement system addresses subjects such as Endocrinology, which are connected to disciplines such as Platelet.
His work on Complement, C1-inhibitor, Atypical hemolytic uremic syndrome and Complement components as part of general Immunology research is frequently linked to Nafamostat mesylate, thereby connecting diverse disciplines of science.
His Factor H research is multidisciplinary, incorporating elements of Complement factor I, Borrelia burgdorferi and Microbiology.
His CD46 research is multidisciplinary, incorporating perspectives in Decay-accelerating factor, Complement factor B and Complement membrane attack complex.
His Alternative complement pathway research incorporates themes from Membranoproliferative glomerulonephritis and Internal medicine.
His most cited work include:
- Eculizumab in severe Shiga-toxin-associated HUS. (331 citations)
- Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update (315 citations)
- Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. (310 citations)
What are the main themes of his work throughout his whole career to date?
Michael Kirschfink mainly investigates Immunology, Complement system, Complement, Antibody and Internal medicine.
His study in Alternative complement pathway, Classical complement pathway, Factor H, Complement membrane attack complex and CD59 is carried out as part of his Complement system studies.
His Classical complement pathway research includes themes of Biochemistry and Complement receptor.
His Factor H study combines topics in areas such as Complement factor I, Borrelia burgdorferi, Microbiology and CD46.
His study looks at the intersection of Complement and topics like Cancer research with Gene silencing.
His studies in Internal medicine integrate themes in fields like Gastroenterology, Endocrinology and Pathology.
He most often published in these fields:
- Immunology (39.74%)
- Complement system (38.43%)
- Complement (17.47%)
What were the highlights of his more recent work (between 2012-2020)?
- Immunology (39.74%)
- Complement system (38.43%)
- Internal medicine (16.16%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Immunology, Complement system, Internal medicine, Eculizumab and Complement.
His Immunology study often links to related topics such as Disease.
As part of one scientific family, Michael Kirschfink deals mainly with the area of Complement system, narrowing it down to issues related to the Ophthalmology, and often Age related and Downregulation and upregulation.
He combines subjects such as Gastroenterology, Complement factor I, Surgery and Oncology with his study of Internal medicine.
His biological study spans a wide range of topics, including Nephrology, Factor H, Belatacept, Monoclonal and Atypical hemolytic uremic syndrome.
His study explores the link between Complement and topics such as Cell biology that cross with problems in Apoptosis, Cell mediated immunity and Membrane.
Between 2012 and 2020, his most popular works were:
- Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach (104 citations)
- An international serum standard for application in assays to detect human complement activation products (104 citations)
- Complement factor H-related hybrid protein deregulates complement in dense deposit disease. (78 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Immune system
Michael Kirschfink mostly deals with Immunology, Complement system, Atypical hemolytic uremic syndrome, Eculizumab and Complement factor I.
His Immunology research focuses on Alternative complement pathway, Hereditary angioedema, C1-inhibitor, Classical complement pathway and Autoantibody.
His work carried out in the field of Complement system brings together such families of science as Complement and Cell biology.
The Eculizumab study combines topics in areas such as Monoclonal, Internal medicine, Hypogammaglobulinemia, Catastrophic antiphospholipid syndrome and Immunoadsorption.
His Complement factor I study combines topics from a wide range of disciplines, such as Endocrinology, Factor H, Macular degeneration and Glaucoma.
Michael Kirschfink works mostly in the field of Factor H, limiting it down to topics relating to C3-convertase and, in certain cases, Molecular biology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
